MOVE Medacta Group

EQS-News: Medacta extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution

EQS Group-News: Medacta Group SA / Key word(s): Product Launch
Medacta extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution

19.10.2021 / 19:00


Media release

Medacta extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution

CASTEL SAN PIETRO, 19 October 2021 - Medacta announces the release of , the newest addition to its MySolutions(R) Personalized Ecosystem. MyKnee R is the unique-on-the-market patient-specific set of 3D-printed blocks that can be directly positioned on the failed primary implant in situ, in order to easily proceed with its replacement. Starting from a CT scan, MySolutions engineers create a 3D reconstruction of the patient's joint where a failed primary implant has been positioned. This reconstruction is then used to accurately plan the positioning of a new prosthesis, chosen from Medacta's portfolio of total knee replacement solutions, ranging from a minimum level of constraint ( and ) to semi- and fully constrained solutions ( and ). MyKnee R is the game-changing technology to facilitate the introduction to total knee revision surgeries, where even highly experienced surgeons are often confronted with complex and time-consuming cases.

Regarding this aspect, Dr. Vicente Leon, the first surgeon to use the system at the Hospital Clínico Universitario Virgen de La Arrixaca (Murcia, Spain), says: "There is nothing better than being able to rely on a patient-specific solution for each kind of knee surgery. Medacta has more than ten years of experience in patient-specific solutions, and I think that the MyKnee R is a great addition to this range of options. Thanks to the 3D preoperative planning tool and the possibility of accurately and quickly replicating the planning during the surgery with the 3D-printed guides, every surgeon can easily achieve conservative bone cuts, none or minimal alteration of the joint line and an optimized alignment of revision implant components, also when revising failed total knee implants."

MyKnee R is part of Medacta's MySolutions ecosystem of personalized medicine products and technologies. Originally introduced as to address an unmet need for better implant positioning in the total knee replacement market, MySolutions can now also be used in hip (, , ), shoulder ( and spine () procedures. In addition to patient-matched surgical guides, MySolutions also includes advanced planning and verification tools, augmented reality-based personalized execution, patient pathway optimization and clinical data collection and analysis.

Dr. Leon concludes "Medacta has a solution for each specific patient's need, providing a comprehensive implant portfolio that covers unicompartmental knee arthroplasties, with the and partial knee systems, total knee arthroplasties, with the medially-stabilized GMK(R) Sphere, and also total knee revisions, with the GMK Revision System. These implants are also available with the ceramic-like coating, which offers a hypoallergenic alternative by reducing the release of metal ions into the patient's body. Now, with MyKnee R, also the MySolutions portfolio is complete, and every kind of knee surgery can be managed using Medacta's patient-specific guides."

MyKnee R is also supported by a tailored educational offering. With an international network of expert surgeons, the is at the forefront of education on total knee revision techniques and products with personalized high-level educational pathways, supporting surgeons with focused activities as they master revision. With Medacta the surgeon is never alone.

Discover more about and .

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: 0

About Medacta
is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1241706

 
End of News EQS Group News Service

1241706  19.10.2021 

fncls.ssp?fn=show_t_gif&application_id=1241706&application_name=news&site_id=research_pool
EN
19/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

ResearchPool Subscriptions

Get the most out of your insights

Get in touch